The effects of the somatostatin analogue, octreotide, on postural hypotension, before and after food ingestion, in primary autonomic failure

1991 ◽  
Vol 1 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Elaine Armstrong ◽  
Christopher J. Mathias
Keyword(s):  
Postural Hypotension ◽  
Autonomic Failure ◽  
Somatostatin Analogue ◽  
Food Ingestion ◽  
Before And After ◽  
Analogue Octreotide

Effect of the Somatostatin Analogue, Octreotide, on Exercise-Induced Hypotension in Human Subjects with Chronic Sympathetic Failure

1995 ◽  
Vol 89 (4) ◽  
pp. 367-373 ◽  
Author(s):  
G. D. P. Smith ◽  
M. Alam ◽  
L. P. Watson ◽  
C. J. Mathias
Keyword(s):  
Blood Pressure ◽  
Postural Hypotension ◽  
Autonomic Failure ◽  
Somatostatin Analogue ◽  
Induced Hypotension ◽  
Post Exercise ◽  
Blood Pressure Fall ◽  
Before And After ◽  
Exercise Induced ◽  
Pressure Fall

1. In autonomic failure, supine exercise lowers blood pressure and worsens postural hypotension. The somatostatin analogue, octreotide, reduces postprandial and postural hypotension, but its effects on exercise-induced hypotension and on postural hypotension post-exercise are unknown. 2. Eighteen subjects with chronic sympathetic denervation were studied; 12 had pure autonomic failure and six had additional neurological features of the Shy—Drager syndrome. Haemodynamic, hormonal and biochemical changes were measured before, during and after incremental supine leg exercise on two occasions: on no treatment and after subcutaneous octreotide. Exercise was performed 120 min after octreotide in eight subjects and 60 min after octreotide in ten subjects. 3. Octreotide did not improve exercise-induced hypotension; the blood pressure fall was greater during exercise, but the blood pressure level was no different than without treatment. Heart rate, stroke distance, cardiac index and systemic vascular resistance were similar at rest and changed to the same degree with exercise on and off octreotide. After octreotide, resting levels of serum growth hormone, plasma noradrenaline, adrenaline and renin were unchanged, but glucose was higher and insulin was lower. There was no change in biochemical and hormone levels during exercise either off or on octreotide. 4. After octreotide, although the rate of blood pressure recovery was similar post-exercise, the levels of blood pressure were higher than in the non-treatment phase and postural hypotension was improved before and after exercise. 5. In conclusion, in primary autonomic failure, octreotide did not improve exercise-induced hypotension in the supine position, suggesting that octreotide-sensitive vasodilatory peptides do not contribute to the blood pressure fall. With octreotide, supine blood pressure levels were higher post-exercise and postural hypotension was improved both before and after exercise.

Prevention of Glucose-Induced Hypotension by the Somatostatin Analogue Octreotide (Sms 201-995) in Chronic Autonomic Failure: Haemodynamic and Hormonal Changes

1989 ◽  
Vol 77 (6) ◽  
pp. 623-628 ◽  
Author(s):  
S. J. Raimbach ◽  
P. Cortelli ◽  
J. S. Kooner ◽  
R. Bannister ◽  
S. R. Bloom ◽  
...  
Keyword(s):  
Blood Flow ◽  
Cardiac Index ◽  
Peripheral Blood ◽  
Autonomic Failure ◽  
Somatostatin Analogue ◽  
Peripheral Blood Flow ◽  
Hormonal Changes ◽  
Induced Hypotension ◽  
Placebo Phase ◽  
Analogue Octreotide

1. The haemodynamic and hormonal changes following glucose ingestion (1 g/kg) were determined before and after pretreatment with either placebo or the somatostatin analogue, octreotide (SMS 201-995, 50 μg sub-cutaneously), in seven patients with chronic autonomic failure 2. In the placebo phase, after glucose, there was a marked and prolonged fall in blood pressure with no change in cardiac index and peripheral blood flow. Plasma insulin and neurotensin levels increased, whereas glucagon, vasoactive intestinal polypeptide, noradrenaline and adrenaline levels were unchanged 3. Octreotide transiently raised blood pressure and prevented glucose-induced hypotension. There were no changes in cardiac index or peripheral blood flow. Plasma insulin and neurotensin levels did not rise. Plasma glucose levels increased more slowly but reached a similar level to the placebo phase 4. We conclude that in autonomic failure patients, glucose-induced hypotension was not accompanied by changes in cardiac index or peripheral blood flow, indicating a lack of compensation to probable splanchnic vasodilatation. The hypotension was prevented by the peptide release inhibitor, octreotide, with no change in cardiac index or in peripheral blood flow, suggesting an effect on the splanchnic vasculature, probably through inhibiting release of vasodilatatory pancreatic and gut peptides.

scholarly journals The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells

2010 ◽  
Vol 70 (2) ◽  
pp. 666-674 ◽  
Author(s):  
Vesna Cerovac ◽  
Jose Monteserin-Garcia ◽  
Hadara Rubinfeld ◽  
Michael Buchfelder ◽  
Marco Losa ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Pituitary Tumor ◽  
Somatostatin Analogue ◽  
Rapamycin Treatment ◽  
Analogue Octreotide

Effect of the Somatostatin Analogue Octreotide Acetate on Hemostasis in Humans

1991 ◽  
Vol 66 (3) ◽  
pp. 283-286 ◽  
Author(s):  
THOMAS E. WITZIG ◽  
LARRY K. KVOLS ◽  
CHARLES G. MOERTEL ◽  
E.J. WALTER BOWIE
Keyword(s):  
Somatostatin Analogue ◽  
Octreotide Acetate ◽  
Analogue Octreotide

PHARMACOKINETICS OF THE LONG-ACTING SOMATOSTATIN ANALOGUE OCTREOTIDE (SMS 201-995) IN ACROMEGALY

1990 ◽  
Vol 32 (5) ◽  
pp. 545-550 ◽  
Author(s):  
J. NICHOLLS ◽  
D. WYNICK ◽  
J. DOMIN ◽  
L. M. SANDLER ◽  
S. R. BLOOM
Keyword(s):  
Somatostatin Analogue ◽  
Long Acting ◽  
Analogue Octreotide
Sign in / Sign up

Export Citation Format

Share Document